Tirzepatide vs Retatrutide: how the evidence compares
By Theo Park · Editor, Privacy & Safety
Updated Jun 2026Tirzepatide and retatrutide are two of the most talked-about metabolic drugs of the decade, and they sit at very different stages of proof. Tirzepatide is FDA-approved, sold as Mounjaro and Zepbound, and backed by large completed trials. Retatrutide is still investigational as of June 2026, with strong early results but no approval yet. This guide walks through what each drug actually is, what the published evidence shows, where that evidence is solid versus thin, and how the two stack up on weight loss, safety, and real-world availability.
Tirzepatide and retatrutide are two of the most talked-about metabolic drugs of the decade, and they sit at very different stages of proof. Tirzepatide is FDA-approved, sold as Mounjaro and Zepbound, and backed by large completed trials. Retatrutide is still investigational as of June 2026, with strong early results but no approval yet. This guide walks through what each drug actually is, what the published evidence shows, where that evidence is solid versus thin, and how the two stack up on weight loss, safety, and real-world availability.
What these drugs are
Both drugs belong to the broader family of incretin-based therapies. They work by mimicking gut and pancreatic hormones that the body normally releases after a meal. These hormones tell the brain you're full, slow how fast the stomach empties, and help the pancreas release insulin when blood sugar rises. The result is less hunger, smaller portions, and steadier blood sugar.
The difference between the two is how many hormone systems they target.
Tirzepatide is a dual agonist. It activates two receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It was the first dual incretin agonist to reach the market.
Retatrutide is a triple agonist. It hits the same two receptors as tirzepatide, GIP and GLP-1, plus a third: the glucagon receptor. Activating the glucagon receptor sounds odd, because glucagon usually raises blood sugar. But in this context it appears to boost energy expenditure and push the liver to burn fat. The bet behind retatrutide is that adding glucagon action drives more weight loss and bigger drops in liver fat than a dual agonist alone.
So the simple way to remember it: tirzepatide pulls two levers, retatrutide pulls three. Whether the third lever is worth it is exactly what the trials are testing.
Why the glucagon receptor is the wild card
It's worth slowing down on the third receptor, because it's the entire reason retatrutide exists as a separate drug. For decades, glucagon was treated as the enemy in metabolic medicine. It raises blood sugar, which is the last thing you want in someone with diabetes. So the obvious question is why anyone would build a weight-loss drug that switches it on.
The answer is that glucagon does two useful things when it's paired with strong GLP-1 action. It increases how many calories the body burns at rest, and it tells the liver to break down stored fat for energy. On its own, the blood-sugar problem would outweigh the benefit. But GLP-1 and GIP push blood sugar down hard enough to cancel out glucagon's sugar-raising effect, leaving the energy-burning and fat-mobilizing effects behind. That balancing act is the scientific bet at the heart of retatrutide.
This also explains why retatrutide's standout result wasn't weight at all, it was liver fat. The liver is where glucagon does much of its work, so a drug that adds glucagon action should, in theory, clear liver fat faster than one that doesn't. The early data fits that theory. Whether the theory holds up in large, long trials is still an open question.
Mechanism head-to-head
| Feature | Tirzepatide | Retatrutide |
|---|---|---|
| Drug class | Dual incretin agonist | Triple-hormone-receptor agonist |
| Receptors targeted | GIP, GLP-1 | GIP, GLP-1, glucagon |
| Third mechanism | None | Glucagon receptor (raises energy burn, mobilizes liver fat) |
| Dosing | Once weekly injection | Once weekly injection |
| Brand names | Mounjaro (diabetes), Zepbound (obesity) | None yet (investigational) |
| Maker | Eli Lilly | Eli Lilly |
| Approval status (June 2026) | FDA-approved | Not approved; in phase 3 |
It's worth noting that both drugs come from the same company, Eli Lilly. That matters when you read the evidence, because nearly all of the funding, trial design, and data analysis traces back to the manufacturer. That doesn't make the data wrong. But it does mean independent, head-to-head trials between the two drugs do not yet exist, and the comparisons below are drawn from separate studies run at different times. Keep that in mind.
The weight loss evidence
This is where most people focus, so let's be precise about what was measured and how strong the proof is.
Tirzepatide: the evidence is mature
Tirzepatide's weight-loss case rests on the SURMOUNT trial program, which is large, peer-reviewed, and complete. The flagship trial, SURMOUNT-1, enrolled 2,539 adults with obesity (or overweight plus a weight-related health problem) who did not have diabetes. Over 72 weeks, participants on the highest dose (15 mg) lost an average of 22.5% of their body weight, compared with about 2.4% on placebo. Lower doses still produced large losses: roughly 16% at 5 mg and 21.4% at 10 mg.
That result was published in the New England Journal of Medicine and confirmed across follow-up trials. The evidence here is about as good as obesity drug evidence gets: large sample, randomized, placebo-controlled, long duration, published in a top journal.
A more recent trial, SURMOUNT-5, compared tirzepatide directly against semaglutide (Wegovy) in adults with obesity. Over 72 weeks, tirzepatide produced more weight loss (about 20% vs about 14%) and a larger drop in waist size. This is one of the few true head-to-head obesity drug trials, and it puts tirzepatide ahead of semaglutide. Notably, no such head-to-head trial exists between tirzepatide and retatrutide.
Retatrutide: the evidence is promising but earlier
Retatrutide's headline numbers are bigger, but the proof is at an earlier and thinner stage.
The phase 2 obesity trial, published in the New England Journal of Medicine in 2023, enrolled 338 adults with obesity. At 48 weeks, the highest dose (12 mg) produced an average weight loss of 24.2%, with the 8 mg dose close behind at 22.8%. Some participants lost far more. These are striking results for a phase 2 study.
But phase 2 trials are smaller and shorter than the trials that support approval. With 338 people, you learn whether a drug works and roughly how safe it is, not the rarer risks or the durability over years. So the 24.2% figure should be read as a strong signal, not a settled fact.
That changed somewhat in 2026. Eli Lilly announced topline results from TRIUMPH-1, the first pivotal phase 3 obesity trial of retatrutide, with roughly 2,300 participants. The company reported average weight loss of about 28.3% at the 12 mg dose, with a large share of participants losing 30% or more of their body weight. If these numbers hold up in full peer-reviewed publication, retatrutide would be the most powerful weight-loss drug studied to date.
Two cautions are important and honest. First, as of June 2026 the TRIUMPH-1 results are a company press announcement, not a fully published, peer-reviewed paper. Topline announcements give the highlights but not the full safety tables or the messier details. Second, additional phase 3 trials (in diabetes and in people with heart disease) are still running. Until those finish and the full data is published, retatrutide's profile is incomplete.
Side-by-side weight loss numbers
| Trial | Drug & dose | Population | Duration | Avg weight loss | Evidence strength |
|---|---|---|---|---|---|
| SURMOUNT-1 | Tirzepatide 15 mg | Obesity, no diabetes (n=2,539) | 72 weeks | ~22.5% | Strong; published, large, phase 3 |
| SURMOUNT-5 | Tirzepatide (vs semaglutide) | Obesity, no diabetes | 72 weeks | ~20% | Strong; head-to-head vs semaglutide |
| Retatrutide phase 2 | Retatrutide 12 mg | Obesity (n=338) | 48 weeks | ~24.2% | Moderate; published but small/short |
| TRIUMPH-1 | Retatrutide 12 mg | Obesity (n~2,300) | ~80 weeks | ~28.3% (topline) | Early; press release, not yet peer-reviewed |
The honest summary: tirzepatide's evidence is deeper and fully published; retatrutide's numbers are higher but rest partly on a small phase 2 trial and an unpublished phase 3 announcement.
Does the weight stay off?
A number on a chart at 72 weeks is not the same as a number that holds for years. This is one of the most important and least discussed parts of the evidence, and it applies to both drugs.
The honest finding from the broader research on this drug class is that the weight comes back when you stop. Trials that took people off the drug saw a meaningful share of the lost weight return over the following year. That's because these drugs treat the biology of appetite and metabolism while you take them; they don't permanently reset it. For most people, staying on the drug is what keeps the weight off, which makes long-term cost and tolerability central, not just the peak loss number.
For tirzepatide, this regain pattern is documented in its own withdrawal trial. For retatrutide, there isn't enough long-term published data yet to say how durable the loss is or how fast it returns after stopping. That's another gap that favors tirzepatide on evidence, even though retatrutide's peak numbers are higher. A drug you understand over years is worth more than a drug you understand over months.
Beyond weight: blood sugar and liver fat
Weight is not the only outcome that matters, especially for people with metabolic disease.
Blood sugar. Both drugs lower blood sugar, which makes sense given their shared GIP and GLP-1 action. Tirzepatide's diabetes evidence is extensive and FDA-approved under the Mounjaro brand. Retatrutide also improved blood sugar in its phase 2 work, and a dedicated phase 3 diabetes trial is underway, but its diabetes data is not yet mature.
Liver fat. This is where retatrutide's third mechanism may stand out. A separate phase 2a trial tested retatrutide in people with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called fatty liver). At 24 weeks, the higher doses produced very large reductions in liver fat, with most participants reaching normal liver-fat levels. The glucagon receptor action is the likely reason, since glucagon pushes the liver to break down fat. Tirzepatide also reduces liver fat, but the early retatrutide liver-fat signal is unusually strong. Again, this comes from a small phase 2a study and needs confirmation.
Safety: what the evidence shows
Both drugs share the same dominant side effect: gut symptoms. That's a class effect of slowing the stomach and acting on appetite circuits.
The most common problems are nausea, vomiting, diarrhea, and constipation. These tend to appear during the dose-escalation phase, when the dose is being slowly raised, and ease off as the body adjusts. Most cases are mild to moderate. Starting low and going up slowly is the standard way to limit them.
In tirzepatide trials, nausea was reported by roughly a quarter to a third of participants depending on dose, with vomiting and diarrhea lower. In the retatrutide phase 2 trial, gut side effects rose with dose, and nausea reached around half of participants at the highest dose, somewhat higher than typical tirzepatide rates, though the trials weren't run head-to-head so direct comparison is rough.
Dose escalation is the practical reason these drugs are tolerable at all. Neither drug is started at its full dose. Instead, treatment begins low and the dose is raised in steps over weeks or months, giving the gut time to adapt. Skipping this slow ramp is the fastest way to trigger severe nausea and vomiting. In the retatrutide phase 2 trial, the dose-escalation schedule mattered: faster escalation produced more gut side effects than slower escalation at the same final dose. This is one reason the unregulated, self-dosed versions of retatrutide sold online are risky. Without a proper titration plan and medical oversight, the side effects are both more likely and more dangerous.
A few other safety points deserve attention:
- Heart rate. Both drugs modestly raise resting heart rate, on the order of a few beats per minute. Retatrutide's increase looked slightly larger in phase 2 but in the same general range. The long-term meaning of this is still being studied.
- Gallbladder problems. Rapid weight loss of any kind raises gallstone risk, and both drugs have shown some gallbladder-related events.
- Thyroid warning. The tirzepatide label carries a boxed warning about thyroid C-cell tumors, based on rodent studies, and advises against use in people with a personal or family history of medullary thyroid cancer or a specific genetic syndrome. As a same-class drug from the same maker, retatrutide will likely face similar scrutiny, but its final label doesn't exist yet.
- Pancreatitis. Inflammation of the pancreas is a known, uncommon risk across this drug class and has been reported with tirzepatide.
The key safety difference is not the type of risk but the depth of knowledge. Tirzepatide has been used by millions and has a real-world safety record plus post-marketing monitoring. Retatrutide has been studied in a few thousand people in trials. Rare side effects only show up once a drug is used widely, so retatrutide's full safety picture simply isn't known yet.
Availability and cost
This is the most practical difference for anyone reading in 2026.
| Factor | Tirzepatide | Retatrutide |
|---|---|---|
| Can you get it prescribed? | Yes (Mounjaro, Zepbound) | No, investigational only |
| FDA approval | Yes | No (NDA filing anticipated, not yet approved) |
| Insurance coverage | Sometimes, varies by plan/indication | None |
| Typical access | Pharmacy with prescription | Clinical trials only |
| Compounded versions | Limited; tied to shortage rules | Sold by some vendors as "research chemical," not approved for human use |
A serious caution on retatrutide: because it isn't approved, the only legitimate way to receive it is through an enrolled clinical trial. Products sold online as retatrutide "for research" are not regulated for human use, are not quality-controlled the way prescription drugs are, and using them is risky. Dose, purity, and sterility are unverified. For more on this gray market, see our guide on compounded GLP-1 peptides and their legal and safety status.
Who each drug is for
Tirzepatide makes sense if you want a treatment available today, with strong published evidence and a prescription path. It's approved for obesity and for type 2 diabetes, has the deepest safety record of the two, and beat semaglutide head-to-head. For most people choosing between an approved drug now and an experimental one, tirzepatide is the evidence-backed option.
Retatrutide is interesting if you're tracking what's next. Its triple-agonist design may push weight loss and liver-fat reduction beyond what dual agonists achieve. But it is not a treatment you can responsibly start in 2026 outside a trial. The right move for an interested patient is to ask a doctor about enrolling in a study, not to buy unregulated product.
It's also worth being clear about who these drugs are not for, regardless of the brand. People with a personal or family history of medullary thyroid cancer or the genetic syndrome MEN 2 are warned off this drug class. People who have had pancreatitis need caution. People with a history of gallbladder disease should know that rapid weight loss can make it worse. Pregnancy is a clear reason to avoid both drugs. And anyone who can't commit to the gradual dose-escalation schedule, or who can't be monitored by a clinician, is a poor candidate. None of this is unique to one drug; it applies across the incretin class.
A reasonable way to think about the choice is in terms of certainty versus ceiling. Tirzepatide offers more certainty: you know it works, you know roughly how well, you know the main risks, and you can get it. Retatrutide offers a higher possible ceiling on results but far less certainty, because the long-term and large-scale data isn't in. Most patients are better served by certainty. The people for whom the ceiling matters most, those with severe obesity or stubborn liver disease, are exactly the people who should pursue it through a trial where the risks are managed.
For a broader look at how these metabolic drugs fit alongside other approaches, see our overview of the retatrutide triple agonist phase 2 results and our review of what is known about retatrutide as a research compound. If you're weighing the wider category, our semaglutide mechanism of action research review covers the most widely used drug in this class.
The bottom line
Tirzepatide and retatrutide are cousins built on the same platform, separated mainly by one extra mechanism and by years of clinical proof. Tirzepatide is the present: approved, published, head-to-head superior to semaglutide, with the deepest safety record. Retatrutide is the likely future: bigger early weight-loss numbers and a striking liver-fat signal, but resting on a small phase 2 trial and a phase 3 announcement that hasn't been fully published or peer-reviewed.
Read the gap in evidence as the real story. The 28% figure for retatrutide is exciting, but it does not yet carry the same weight as the 22.5% figure for tirzepatide, which has been published, replicated, and used in the real world. Bigger numbers from smaller, earlier, manufacturer-run trials should raise your interest, not settle your decision.
Frequently Asked Questions
Is retatrutide better than tirzepatide?
On the raw weight-loss numbers, retatrutide's early trials show larger average losses (about 24% in phase 2, about 28% in a 2026 phase 3 topline) than tirzepatide's 22.5% in SURMOUNT-1. But "better" depends on more than the headline number. Tirzepatide's evidence is fully published, larger, and proven over years; retatrutide's is earlier and partly unpublished. No trial has ever compared the two drugs directly, so any "better" claim is an indirect comparison, not a settled fact.
Is retatrutide available by prescription in 2026?
No. As of June 2026 retatrutide is investigational and not FDA-approved. The only legitimate way to receive it is through an enrolled clinical trial. Products sold online as retatrutide are not regulated for human use, and their dose, purity, and sterility are unverified.
What is the main difference between the two drugs?
Tirzepatide activates two hormone receptors (GIP and GLP-1), while retatrutide adds a third, the glucagon receptor. The glucagon action is thought to raise energy expenditure and pull fat out of the liver, which may explain retatrutide's larger early weight-loss and liver-fat results. Both are once-weekly injections made by Eli Lilly.
Why is retatrutide's evidence considered weaker?
Most of retatrutide's published data comes from a phase 2 trial of only 338 people over 48 weeks. Its phase 3 obesity results were announced by the manufacturer in 2026 but have not yet appeared as a full, peer-reviewed publication. Tirzepatide, by contrast, has multiple large, published, peer-reviewed phase 3 trials and a real-world safety record from millions of users.
Do tirzepatide and retatrutide have the same side effects?
Largely yes. Both cause gut symptoms, mainly nausea, vomiting, and diarrhea, that are worst during dose escalation and usually fade. Both modestly raise heart rate and carry gallbladder risk with rapid weight loss. The key difference is depth of knowledge: tirzepatide's safety is well documented, while retatrutide's rarer and long-term risks are still unknown.
Sources and further reading
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (Jastreboff et al., NEJM 2023, PubMed) — the primary phase 2 obesity trial reporting up to 24.2% weight loss at 48 weeks.
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, Jastreboff et al., NEJM 2022, PubMed) — the phase 3 trial reporting up to 22.5% weight loss at 72 weeks.
- PubMed search: tirzepatide vs semaglutide for obesity (SURMOUNT-5 head-to-head) — head-to-head obesity trial literature.
- FDA Prescribing Information for ZEPBOUND (tirzepatide), 2023 label — official label including the boxed thyroid C-cell tumor warning and safety data.
- Retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (Nature Medicine, 2024) — the liver-fat reduction evidence.
- PubMed search: retatrutide obesity phase 3 — the developing phase 3 (TRIUMPH) literature.
- PubMed search: retatrutide triple agonist mechanism — background on the GIP/GLP-1/glucagon mechanism.
This article is for general information and education only. It is not medical advice. Talk with a licensed healthcare provider before starting, stopping, or changing any medication or therapy.
On Google
Get our answers in your Google results.
Add Peptide Front as a preferred source and Google will surface our peptide research more often — in Top Stories and AI answers, marked with a preferred badge. One tap, free, undo anytime.
Add us as a preferred sourceOpens Google's source preferences for peptidefront.com. No sign-up with us — it's a Google setting.